来自全球30多个国家，70多个不同机构的科学家、医生、资助者和政策制定者发起了一个国际联盟，以便能在某些资源匮乏的环境下，一同应对COVID-19冠状病毒病疫情。COVID-19冠状病毒病临床研究联盟的成立，旨在提供与加快COVID-19冠状病毒病预防与治疗相关的研究，尤其是在那些被病毒肆虐、卫生医疗系统条件不足与脆弱而导致弱势群体健康受到巨大影响的地区
在今日《LANCET》期刊上所发表的评论中提到，联盟成员认为；非洲、拉丁美洲、东欧和部分亚洲国家迫切需要国际性的研究合作与协调，以便能加快研究进度，并让其能适应在资源有限的地区下顺利进行，从而更有效率地去应对在全球各地日益恶化的大流行病。
该联盟汇集了一众来自世界各地，且前所未有的卫生专家组合；这其中包括了公共部门研究机构、卫生部、学术界、非营利性研究和发展组织、非政府组织、国际组织和资助者。他们都齐心致力为资源有限的地区寻找COVID19冠状病毒病的处理方案。
笔者们亦表示，其中针对COVID-19冠状病毒病的一个重要研究对策已经开始：即世界卫生组织（WHO）所引领进行的SOLIDARITY试验 – 这绝对是一项前所未有的全球共同努力。不过，笔者们也发现目前已经有将近600个已注册的COVID-19冠状病毒病临床试验，但在资源有限地区所计划与进行的试验却占了非常小的数目。正因如此，笔者们承诺会分享他们的技术专长和临床试验能力，以便能加快在资源有限地区的COVID-19冠状病毒病相关研究。
无可否认，这项严峻挑战的规模显然超出了任何一个组织的能力范围。为此联盟将会推动以互相协调的方式，以便能一致性地收集、整合并实时分享来自世界各地的所有数据。这样一来，世界卫生组织（WHO）和其他国家们能迅速且有效地循证决策，来定制有关政策与实施方案。
“我们非常欢迎这个联盟的成立，它妥善利用了现有来自跨国与跨科专业专才，在中低收入国家所进行的临床试验，并协助世界卫生组织 (WHO) 在应对COVID-19冠状病毒全球疫情时的协调角色。” 世界卫生组织首席科学家Soumya Swaminathan博士同时也认为：“尽管今天这次大流行病的中心是在其他地方，但现在我们必须为这起全球大流行病在资源有限的环境下所带来的后果做好万全的准备，否则我们将失去更多宝贵的生命。”
此外，联盟成员也呼吁各方作出具体承诺以确保可及性（access），从而能以最快的速度为有限资源地区制造出有效，可及并负担得起的治疗方案，让抗疫达到事半功倍之效。
迄今为止，已有70个组织加入了这个联盟，他们也一并呼吁其他愿意贡献现有能力的组织加入这个联盟。欲了解更多信息，请与COVID-19冠状病毒病临床研究联盟联系。邮址是: info@covid19crc.org
媒体联系
General English-language inquiries
Ilan Moss: imoss@dndi.org
Paula Feery: paula.feery@iddo.org
Spanish and Portuguese language inquiries
Marcela Dobarro: mdobarro@dndi.org
Inquiries for Africa
Linet Atieno Otieno: latieno@dndi.org
Inquiries for South-East Asia
Molly Jagpal: mjagpal@dndi.org
Inquiries for India
Manisha Sharma: msharma@dndi.org
French-language inquiries
Frédéric Ojardias : fojardias@dndi.org
签署单位与个人包括
Noor Hisham Abdullah, Ministry of Health, Malaysia;
Marcelo Claudio Abril, Mundo Sano Foundation, Argentina;
Yussof Ahkmal, Clinical Research Malaysia, Malaysia;
Ashenafi Tazebew Amare, University of Gondar, Ethiopia;
John H Amuasi, The African coalition for Epidemic Research Response and Training (ALERRT), Kwame Nkrumah University of Science and Technology, Ghana
Prasert Auewarakul, Mahidol University, Thailand;
Augustin Augier, ALIMA, France;
Martin Avaro, National Administration of Laboratories and Health Institutes of Argentina (ANLIS), Argentina;
Manica Balasegaram, GARDP, Switzerland;
Emmanuel Baron, Epicentre, France;
Elsa Baumeister, National Administration of Laboratories and Health Institutes of Argentina (ANLIS), Argentina;
Daniel G. Bausch, UK Public Health Rapid Support Team & London School of Hygiene & Tropical Medicine, UK;
Philip Bejon, KEMRI-Wellcome Trust Research Programme, Kenya;
Estafanio Benedetti, National Administration of Laboratories and Health Institutes of Argentina (ANLIS), Argentina;
Anders Björkman, Karolinska Institutet, Sweden;
Catharina Boehme, FIND, Switzerland;
Maria Elena Botazzi, Baylor College of Medicine, USA;
Joel G Breman, American Society of Tropical Medicine and Hygiene (ASTMH), USA;
Dirk Heinz, DZIF, Germany;
Pedro Cahn, Huesped Foundation, Argentina;
Gail Carson, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), UK;
Roberto Chuit, National Academy of Medicine of Buenos Aires, Argentina;
Gavin Churchyard, Arum Institute;
John Clemens, icddr,b, Bangladesh;
Stewart Cole, Pasteur Institute, France;
Maura Dandri, DZIF, Germany;
Nick Day, Mahidol Oxford Tropical Medicine Research Unit, Thailand;
Arjen Dondorp, Critical Care Asia Network, Mahidol Oxford Tropical Medicine Research Unit, Thailand;
Paul Farmer, Harvard Medical School, USA;
Jeremy Farrar, Wellcome, UK;
Abebaw Fekadu, CDT-Africa, Addis Ababa University, Ethiopia;
Antoine Flahault, Institute of Global Health, University of Geneva, Switzerland;
Patricia Garcia, Universidad Peruana Cayetano Heredia, Peru;
Steven Gordon, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Malawi;
Anastasia Guantai, University of Nairobi, Kenya;
Philippe J Guerin, Infectious Diseases Data Observatory (IDDO), University of Oxford, UK;
Dirk Heinz, DZIF, Germany;
Abraham Hodgson, Ghana Health Service, Ghana;
Peter Horby, ISARIC & the African Coalition for Epidemic Research, Response and Training (ALERRT), UK;
Peter Hotez, Baylor College of Medicine, USA;
Muntaser Ibrahim, Institute of Endemic Diseases, University of Khartoum, Sudan;
Chikwe Ihekweazu, Nigeria Centre for Disease Control, Nigeria;
Timo Jaeger, DZIF German Center for Infection Research, Germany;
Jean Jannin, Société Francophone de Médecine Tropicale et Santé Internationale, France;
Gagandeep Kang, Translational Health Science and Technology Institute of India, India;
Marie-Paule Kieny, Drugs for Neglected Diseases initiative, Switzerland;
Yeri Kombe, KEMRI, Kenya;
Hans-Georg Kraeusslich, DZIF German Center for Infection Research, Germany;
David Lalloo, Liverpool School of Tropical Medicine, UK;
Trudie Lang, The Global Health Network, UK;
Ramanan Laxminarayan, Center for Disease Dynamics, Economics & Policy, USA;
Honorati Masanja, Ifakara Health Institute, Tanzania;
Marcela Mercado, Instituto Nacional de Salud de Colombia, Colombia;
Hassan Mshinda, Botnar Foundation, Tanzania;
Joia Mukherjee, Partners in Health, USA;
Trevor Mundel, Bill & Melinda Gates Foundation, USA;
Jean-Jacques Muyembe, Institut National pour la Recherche Biomédicale, Democratic Republic of Congo;
Denise Naniche, ISGlobal, Spain;
Barnabas Nawangwe, Makerere University, Uganda;
Francine Ntoumi, Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Disease Epidemics (PANDORA-ID-NET), Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo;
Marta Ospina, Instituto Nacional de Salud de Colombia;
Michael Parker, ETHOX Centre, University of Oxford, UK;
Bernard Pécoul, Drugs for Neglected Diseases initiative, Switzerland;
Antonio Plasència Taradach, ISGlobal, Spain;
Andrea Pontoriero, National Administration of Laboratories and Health Institutes of Argentina (ANLIS), Argentina;
Richard Price, Menzies School of Health Research, Australia;
David Reddy, Medicines for Malaria Venture, Switzerland;
John Reeder, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Switzerland;
Philip J Rosenthal, UCSF, USA;
John Arne Røttingen, Norwegian Research Council, Norway;
Maro Russo, National Administration of Laboratories and Health Institutes of Argentina (ANLIS), Argentina;
Fred Siyoi, Kenya Pharmacy & Poisons Board, Kenya;
Munir S. Skaf, University of Campinas, Brazil;
Nathalie Strub-Wourgaft, Drugs for Neglected Diseases initiative, Switzerland;
Omar Sued,Huesped Foundation;
Marcel Tanner, Swiss Academy of Arts and Sciences, Switzerland;
Guy Thwaites, Oxford University Clinical Research Unit, Vietnam;
Faustino Torrico, CEADES Foundation, Bolivia;
Nísia Trinidade Lima, Fundação Oswaldo Cruz (Fiocruz), Brazil;
Jürg Utzinger, Swiss Tropical and Public Health Institute, Switzerland;
George M Varghese, Christian Medical College, Vellore, India;
Nicholas J. White, Mahidol Oxford Tropical Medicine Research Unit, Thailand;
Marc-Alain Widdowson, Institute of Tropical Medicine, Belgium;
Charles S Wiysonge, South African Medical Research Council, South Africa;
Tassew Woldehanna, Addis Ababa University, Ethiopia;
Katharine Wright, Nuffield Council of Bioethics, UK;
Yazdan Yazdanpanah, REACTing & INSERM, France.
